Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2022 | Leveraging technology to detect and mitigate CAR-T therapy-related toxicity remotely

Surbhi Sidana, MD, Mayo Clinic, Stanford, CA, discusses the possibility of detecting and mitigating adverse events caused by CAR-T therapy including cytokine release syndrome (CRS) and neurotoxicity remotely using medical-grade devices to reduce the time that patients spend in the hospital. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.